This project has been made entirely with Chat-GPT, as i know close to nothing about C#, so feel free to think bad about the code. It's not my code anyway :) This ...

A Complete Python client package for developing python code and apps for Alfresco. Great for doing AI development with Python based LangChain, LlamaIndex, neo4j-graphrag, etc. Also great for creating ...

SECAUCUS, N.J., Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) stating ...

Today, a brief rundown of news involving the Food and Drug Administration and Gilead Sciences, as well as updates from AC Immune, Agios Pharmaceuticals, Merck KGaA that you may have missed. AbbVie ...

SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced ...

Abstract: Organizations that transition to microservices architectures see their API count rise quickly because they must continuously create and modify APIs through decomposition and evolution and ...

1 Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China 2 Department of Dermatology, Mianyang ...

The FDA closed out 2025 with a pair of complete response letters, cratering the share prices of Corcept Therapeutics and Outlook Therapeutics. Both companies reported that the agency had rejected a ...

As 2025 ends, tensions between China and Taiwan are higher — and more overt — than at any point in recent years, fueled by expanded U.S. military support for Taipei, increasingly bold warnings from ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...